KEDPLASMA Acquires 2 Centers from ImmunoTek

KEDPlasma, a subsidiary of Kedrion Biopharma, has announced the acquisition of two plasma collection centers from ImmunoTek Bio Centers, LLC, effective January 1, 2016.  KEDPlasma collects plasma for its parent company, which produces plasma-derived medicinal products treating rare diseases, disorders and conditions such as hemophilia and immune system deficiencies.  The two new centers, located in Dothan, Alabama and Hattiesburg, Mississippi bring KEDPlasma’s total to twelve US collection centers, and are part of a five year plan to increase the number of centers the company operates. “We are very proud to add these centers to the KEDPlasma family,” noted Helen Nasser, the company’s Managing Director, “The addition of the centers will allow us to continue our growth plan of supplying the highest quality plasma to our parent company, Kedrion Biopharma.”  ImmunoTek has, in fact, been supplying Kedrion Biopharma with plasma from these centers since they were opened in 2014.  They are FDA licensed and approved by the European Authority.  ImmunoTek Bio Centers, LLC CEO & President, Jerome Parnell III stated “The transition of these assets represents ImmunoTek’s ability to provide maximum flexibility to all of our customer’s strategic plasma supply needs, as well as strengthen our relationship with a strong partner in the biopharma space such as Kedrion.”



KEDPlasma was established in 2004, as a subsidiary of Kedrion Biopharma, which is also the parent company of Kedrion Biopharma, Inc.  Kedrion Biopharma, Inc. and KEDPlasma are both headquartered in the United States.  KEDPlasma’s twelve US collection centers are located in Alabama, California, Florida, New York, Mississippi, North Carolina, South Carolina, Tennessee, and Virginia and employ more than 500 people.  This high quality product is the vital raw material that allows Kedrion Biopharma to produce plasma-derived therapies that treat and prevent serious diseases and conditions such as hemophilia, immune system deficiencies and hemolytic disease of the fetus and newborn (HDFN).

Headquartered in Tuscany, Italy, Kedrion Biopharma has a market presence in more than 100 countries. In the field of plasma derivatives, the company is the world’s 5th most important player in terms of revenues. Its largest and fastest growing market is the United States, where it has established US headquarters in Fort Lee, NJ. Italy is its next most important market, followed by Turkey, Mexico and Russia. In 2014, Kedrion’s gross revenues reached more than 466.3 million Euros (more than $508 million, nearly $175 million in the US alone). The company employs 2200 people worldwide.

Kedrion acts as a life-sustaining bridge, as a vital connection between donors and recipients and operates on a global scale with the aim of expanding patients’ access to available treatments. Kedrion places a high value not only on the welfare of those who benefit from its products but also on the people and communities where it operates.

Following a vertically integrated business model, Kedrion manages the entire plasma transformation cycle from supply and production to distribution.  In Italy, Kedrion is a partner of the National Health Service and collaborates in pursuing self-sufficiency in the development and supply of plasma-derived medicinal products.  The company’s goal is to foster self-sufficiency of plasma-derived therapies worldwide and to bring healthier and less restricted lives to people everywhere who suffer from rare disorders.

Kedrion has five production plants:  three in Italy (a new plant in Castelvecchio Pascoli, which is nearing completion, and one in Bolognana, both in the province of Lucca, and one in Sant’Antimo, Naples); one in Hungary (Gödöllő, Budapest); and one in the United States (Melville, NY). A facility in Siena, Tuscany, specializes in research and development of orphan drugs.

KEDPlasma currently operates twelve plasma collection centers in the United States, four centers in Germany and three centers in Hungary, with all centers having approval by European authorities and/or the US Food and Drug Administration. The company’s collection center in Buffalo, New York is specialized in collecting hyper-immune Anti-D human plasma for the manufacture of an Anti-D immunoglobulin pharmaceutical product for the prevention of hemolytic disease of the fetus and newborn (HDFN).

State-of-the-art production facilities producing a wide range of products and an unwavering commitment to research and development are the key factors of Kedrion’s success.